Inotek Pharmaceuticals Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
Inotek Pharmaceuticals General Information
Description
Provider of clinical-stage bio-pharmaceutical services intended for providing medicine and mitigating the cellular damage caused by ischemic reperfusion injuries. The company's clinical-stage bio-pharmaceutical services focus on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, thereby enabling scientists and physicians to harness the cytoprotective properties of adenosine.
Contact Information
Website
www.inotekpharma.comCorporate Office
- 131 Hartwell Avenue
- 1st Floor, Suite 105
- Lexington, MA 02421
- United States
Corporate Office
- 131 Hartwell Avenue
- 1st Floor, Suite 105
- Lexington, MA 02421
- United States
Inotek Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 04-Jan-2018 | Completed | Profitable | |||
| 13. Secondary Transaction - Open Market | 14-Apr-2017 | Completed | Clinical Trials - Phase 2 | |||
| 12. PIPE | 01-Aug-2016 | Completed | Profitable | |||
| 11. Secondary Transaction - Open Market | 15-Apr-2016 | Completed | Clinical Trials - Phase 2 | |||
| 10. 2PO | 12-Aug-2015 | Completed | Clinical Trials - Phase 2 | |||
| 9. IPO | 17-Feb-2015 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series AA) | 27-Sep-2013 | Completed | Clinical Trials - General | |||
| 7. Mezzanine | 30-Jun-2013 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series AA) | 15-Jul-2011 | $9.1M | $101M | Completed | Clinical Trials - General | |
| 5. Later Stage VC (Series D) | 11-Jun-2010 | $18M | $92.3M | Completed | Clinical Trials - General |
Inotek Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series AA |
Inotek Pharmaceuticals Comparisons
Industry
Financing
Details
Inotek Pharmaceuticals Competitors (101)
One of Inotek Pharmaceuticals’s 101 competitors is Foventa Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| RHEACELL | Corporate Backed or Acquired | Heidelberg, Germany | ||||
| Santhera Pharmaceuticals Holding | Formerly VC-backed | Pratteln, Switzerland |
Inotek Pharmaceuticals Patents
Inotek Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2995175-A1 | Gate for use in enclosure for passage of piglets, has blocking unit arranged to take up blocked position in which each strip is able to freely move on only one side in balance position and not on another side in balance position | Inactive | 10-Sep-2012 | ||
| FR-2991847-B1 | Oscillating ventilation trappe around an oscillation axis for a pitch of a farm building | Inactive | 13-Jun-2012 | ||
| FR-2991847-A1 | Ventilation hatch for pit in livestock building, has flap mounted on frame and movable between open position in which air is allowed to pass through ventilation hatch, and closed position in which air is prevented from crossing hatch | Active | 13-Jun-2012 | ||
| FR-2964530-B1 | Animal feed dispensing device | Inactive | 13-Sep-2010 | ||
| FR-2964530-A1 | Dry food e.g. pellet, distributing device for pigs, has stopblock integrated with stopper and extending below stopper till its height such that stopper is accessible by livestock animal, where stopper is supported on base | Active | 13-Sep-2010 | A01K5/0233 |
Inotek Pharmaceuticals Signals
Inotek Pharmaceuticals Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bio*One Capital | Corporate Venture Capital | Minority | ||
| Care Capital | Venture Capital | Minority | ||
| Devon Park Bioventures | Venture Capital | Minority | ||
| EDBI | Venture Capital | Minority | ||
| Hercules Capital (San Mateo) | Lender/Debt Provider | Minority |
Inotek Pharmaceuticals Acquisitions (1)
Inotek Pharmaceuticals’s most recent deal was a Reverse Merger with Rocket Pharmaceuticals. The deal was made on 04-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals | 04-Jan-2018 | Reverse Merger | Biotechnology |
Inotek Pharmaceuticals FAQs
-
When was Inotek Pharmaceuticals founded?
Inotek Pharmaceuticals was founded in 1999.
-
Where is Inotek Pharmaceuticals headquartered?
Inotek Pharmaceuticals is headquartered in Lexington, MA.
-
What is the size of Inotek Pharmaceuticals?
Inotek Pharmaceuticals has 4 total employees.
-
What industry is Inotek Pharmaceuticals in?
Inotek Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Inotek Pharmaceuticals a private or public company?
Inotek Pharmaceuticals is a Private company.
-
What is Inotek Pharmaceuticals’s current revenue?
The current revenue for Inotek Pharmaceuticals is .
-
How much funding has Inotek Pharmaceuticals raised over time?
Inotek Pharmaceuticals has raised $273M.
-
Who are Inotek Pharmaceuticals’s investors?
Bio*One Capital, Care Capital, Devon Park Bioventures, EDBI, and Hercules Capital (San Mateo) are 5 of 12 investors who have invested in Inotek Pharmaceuticals.
-
Who are Inotek Pharmaceuticals’s competitors?
Foventa Therapeutics, Genentech, Ability Pharma, RHEACELL, and Santhera Pharmaceuticals Holding are some of the 101 competitors of Inotek Pharmaceuticals.
-
When was Inotek Pharmaceuticals acquired?
Inotek Pharmaceuticals was acquired on 04-Jan-2018.
-
Who acquired Inotek Pharmaceuticals?
Inotek Pharmaceuticals was acquired by Rocket Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process